Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFQ056 for levodopa-induced dyskinesia in Parkinson's disease
2007-002900-16Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing AFQ056 + levodopa with Placebo + levodopa (2 arms). Primary endpoints: Anti-dyskinetic efficacy by Lang-Fahn Activities of Daily Living Dyskinesia Scale and Background, demographic and administrative assessments. Started Aug 2007; status: completed.
02
Drugs
mavoglurant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2007-002900-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002900-16.